Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.

[1]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Reiffers,et al.  Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients. , 2009 .

[3]  P. Moreau,et al.  High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial. , 2009 .

[4]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[5]  M. Baccarani,et al.  Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response , 2009, Clinical Cancer Research.

[6]  K. Rezvani,et al.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.

[7]  J. Bussel,et al.  Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study , 2008 .

[8]  J. Reynolds,et al.  The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. , 2008 .

[9]  M. Goodell,et al.  CD81 Is Essential for HSC Self-Renewal through Suppressing Proliferation , 2008 .

[10]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[11]  H. Kantarjian,et al.  Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. , 2008, Blood.

[12]  H. Kantarjian,et al.  Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia , 2008, Cancer.

[13]  Z. Rudzki,et al.  BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria , 2007, Clinical Cancer Research.

[14]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[15]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[16]  J. Goldman,et al.  Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia , 2006, Leukemia.

[17]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[18]  M. Baccarani,et al.  Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients , 2006, Clinical Cancer Research.

[19]  T. Hughes,et al.  Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL , 2006, Leukemia.

[20]  P. Paschka,et al.  Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C , 2003, Leukemia.

[21]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[22]  W. Siegert,et al.  Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia , 2003, Leukemia.

[23]  P. Paschka,et al.  Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission , 2003, Leukemia.

[24]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[25]  H. Kantarjian,et al.  Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2002, Blood.

[26]  P. Paschka,et al.  Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α , 2002, Leukemia.

[27]  C. Craddock,et al.  Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse , 2001, British journal of haematology.

[28]  L. Beppu,et al.  The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. , 2001, Blood.

[29]  C. Craddock,et al.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2001, Blood.

[30]  J. Goldman,et al.  Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. , 1996, Blood.

[31]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[32]  G. Saglio,et al.  Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories , 2008, Leukemia.

[33]  S. Branford.  Chronic myeloid leukemia: molecular monitoring in clinical practice. , 2007, Hematology. American Society of Hematology. Education Program.

[34]  J. Cayuela,et al.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2007, Blood.

[35]  T. Hughes,et al.  Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. , 2006, Blood reviews.